These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37313358)

  • 1. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection.
    Michos ED; Bakris GL; Rodbard HW; Tuttle KR
    Am J Prev Cardiol; 2023 Jun; 14():100502. PubMed ID: 37313358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
    Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
    Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.
    Kelly M; Lewis J; Rao H; Carter J; Portillo I; Beuttler R
    Pharmacotherapy; 2022 Dec; 42(12):921-928. PubMed ID: 36271706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
    Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
    Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Gu X; Jiang S; Yang Y; Li W
    Diabetol Metab Syndr; 2024 Jan; 16(1):14. PubMed ID: 38212831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Chu CD; Peralta CA; Du Y; Singh R; Kong SX; Tuot DS; Shlipak MG; Estrella MM
    Diabetes Care; 2022 Dec; 45(12):2900-2906. PubMed ID: 36156061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
    Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
    Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Xu Y; Fu EL; Clase CM; Mazhar F; Jardine MJ; Carrero JJ
    Kidney Int; 2022 Feb; 101(2):360-368. PubMed ID: 34826514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020.
    Jacobs JA; Zheutlin AR; Derington CG; King JB; Pandey A; Bress AP
    Am J Prev Cardiol; 2024 Mar; 17():100624. PubMed ID: 38125205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kunutsor SK; Khunti K; Seidu S
    J R Soc Med; 2023 Sep; ():1410768231198442. PubMed ID: 37734450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
    Nair R; Mody R; Yu M; Cowburn S; Konig M; Prewitt T
    Diabetes Ther; 2022 Dec; 13(11-12):1921-1932. PubMed ID: 36131064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
    Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
    JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Investigation on the Efficacy of Glucagon-Like Peptide 1 Receptor Agonists Drugs in Reducing Urine Albumin-to-Creatinine Ratio in Patients With Type 2 Diabetes: A Potential Treatment for Diabetic Nephropathy.
    Yarlagadda C; Abutineh M; Reddy AJ; Landau AB; Travis LM; Perrone CG; Idriss A; Patel R
    Cureus; 2023 Mar; 15(3):e36438. PubMed ID: 37090383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure.
    Cromer SJ; Lauffenburger JC; Levin R; Patorno E
    Diabetes Care; 2023 Jan; 46(1):65-74. PubMed ID: 36383481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register.
    Eliasson B; Ekelund J; Holmberg CN; Wolden ML; Matthiessen KS; James S
    Eur J Prev Cardiol; 2023 May; 30(7):546-551. PubMed ID: 36567502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
    Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
    Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.